ERCC5 and cancer: By analyzing a larger number of studies than the previous meta-analysis [84], [85], our meta-analysis included 32,162 cases and 39,858 controls (from 66 studies) for XPG Asp1104His and 17,864 cases and 20,578 controls (from 32 studies) for XPF Arg415Gln to perform the two gene polymorphisms and cancer risk.